A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
Status:
Completed
Trial end date:
2016-11-17
Target enrollment:
Participant gender:
Summary
For patients with non-resectable cholangiocarcinoma, gemcitabine with cisplatin is considered
as the reference treatment in first line chemotherapy. However, the outcomes of these
patients remain limited and therefore more effective drugs are warranted. The context of the
disease and current data on sunitinib suggest that sunitinib may have activity in patients
with advanced non resectable cholangiocarcinoma.
Thereby, it is proposed to conduct an open label single arm trial aiming evidencing activity
of sunitinib in such a patient population.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)